JOP20230032A1 - تركيبة جديدة مانعة للحمل تعطى عن طريق الفم ذات إطلاق معدل - Google Patents
تركيبة جديدة مانعة للحمل تعطى عن طريق الفم ذات إطلاق معدلInfo
- Publication number
- JOP20230032A1 JOP20230032A1 JOJO/P/2023/0032A JOP20230032A JOP20230032A1 JO P20230032 A1 JOP20230032 A1 JO P20230032A1 JO P20230032 A JOP20230032 A JO P20230032A JO P20230032 A1 JOP20230032 A1 JO P20230032A1
- Authority
- JO
- Jordan
- Prior art keywords
- release oral
- new modified
- oral contraceptive
- contraceptive formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382753.0A EP3954364A1 (en) | 2020-08-14 | 2020-08-14 | New modified release oral contraceptive composition |
| PCT/EP2021/072584 WO2022034209A1 (en) | 2020-08-14 | 2021-08-13 | New modified release oral contraceptive composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230032A1 true JOP20230032A1 (ar) | 2023-02-13 |
Family
ID=72145348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0032A JOP20230032A1 (ar) | 2020-08-14 | 2023-02-13 | تركيبة جديدة مانعة للحمل تعطى عن طريق الفم ذات إطلاق معدل |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12409141B2 (enExample) |
| EP (2) | EP3954364A1 (enExample) |
| JP (1) | JP2023538030A (enExample) |
| KR (1) | KR20230067614A (enExample) |
| CN (1) | CN116322701A (enExample) |
| AU (1) | AU2021325372A1 (enExample) |
| BR (1) | BR112023002654A2 (enExample) |
| CA (1) | CA3191326A1 (enExample) |
| CL (1) | CL2023000450A1 (enExample) |
| CO (1) | CO2023002874A2 (enExample) |
| CR (1) | CR20230127A (enExample) |
| DO (1) | DOP2023000029A (enExample) |
| EC (1) | ECSP23016038A (enExample) |
| IL (1) | IL300578A (enExample) |
| JO (1) | JOP20230032A1 (enExample) |
| MX (1) | MX2023001868A (enExample) |
| PE (1) | PE20231378A1 (enExample) |
| PY (1) | PY2168235A (enExample) |
| UY (1) | UY39379A (enExample) |
| WO (1) | WO2022034209A1 (enExample) |
| ZA (1) | ZA202303273B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260021110A1 (en) * | 2024-07-18 | 2026-01-22 | Chemo Research, S.L. | Methods of oral contraception by controlled release of dienogest and ethynyl estradiol |
| WO2026146125A1 (en) | 2024-12-30 | 2026-07-09 | Chemo Research, S.L. | Treatment of hirsutism, polycystic ovarian syndrome and other associated conditions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US7589082B2 (en) | 2003-06-13 | 2009-09-15 | Skendi Finance Ltd | Pharmaceutical formulation for contraception and hormone-replacement therapy |
| EP1690529A1 (de) | 2005-02-15 | 2006-08-16 | Schering AG | Feste perorale Arzneiform zur Kontrazeption, die Dienogest und Ethinylestradiol enthält |
| DK1848406T3 (da) * | 2005-02-15 | 2008-09-15 | Jenapharm Gmbh | Fast, penoral lægemiddelform til kontraception, der indeholder dienogest og ethynylestradiol |
| DE102005034498A1 (de) * | 2005-07-20 | 2007-01-25 | Grünenthal GmbH | Orale Kontrazeption mit Trimegeston |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
-
2020
- 2020-08-14 EP EP20382753.0A patent/EP3954364A1/en not_active Withdrawn
-
2021
- 2021-08-13 US US18/021,165 patent/US12409141B2/en active Active
- 2021-08-13 WO PCT/EP2021/072584 patent/WO2022034209A1/en not_active Ceased
- 2021-08-13 PY PY202102168235A patent/PY2168235A/es unknown
- 2021-08-13 PE PE2023000270A patent/PE20231378A1/es unknown
- 2021-08-13 AU AU2021325372A patent/AU2021325372A1/en active Pending
- 2021-08-13 JP JP2023511588A patent/JP2023538030A/ja active Pending
- 2021-08-13 IL IL300578A patent/IL300578A/en unknown
- 2021-08-13 EP EP21762678.7A patent/EP4196098A1/en active Pending
- 2021-08-13 CN CN202180070759.5A patent/CN116322701A/zh active Pending
- 2021-08-13 CR CR20230127A patent/CR20230127A/es unknown
- 2021-08-13 UY UY0001039379A patent/UY39379A/es unknown
- 2021-08-13 MX MX2023001868A patent/MX2023001868A/es unknown
- 2021-08-13 KR KR1020237008915A patent/KR20230067614A/ko active Pending
- 2021-08-13 BR BR112023002654A patent/BR112023002654A2/pt unknown
- 2021-08-13 CA CA3191326A patent/CA3191326A1/en active Pending
-
2023
- 2023-02-10 DO DO2023000029A patent/DOP2023000029A/es unknown
- 2023-02-13 JO JOJO/P/2023/0032A patent/JOP20230032A1/ar unknown
- 2023-02-14 CL CL2023000450A patent/CL2023000450A1/es unknown
- 2023-03-02 ZA ZA2023/03273A patent/ZA202303273B/en unknown
- 2023-03-06 EC ECSENADI202316038A patent/ECSP23016038A/es unknown
- 2023-03-09 CO CONC2023/0002874A patent/CO2023002874A2/es unknown
-
2024
- 2024-05-09 US US18/660,021 patent/US12409142B2/en active Active
-
2025
- 2025-08-07 US US19/293,837 patent/US20260027058A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY39379A (es) | 2022-01-31 |
| CO2023002874A2 (es) | 2023-04-05 |
| CR20230127A (es) | 2023-06-23 |
| MX2023001868A (es) | 2023-05-09 |
| CN116322701A (zh) | 2023-06-23 |
| US12409141B2 (en) | 2025-09-09 |
| DOP2023000029A (es) | 2023-07-09 |
| IL300578A (en) | 2023-04-01 |
| PE20231378A1 (es) | 2023-09-07 |
| US20260027058A1 (en) | 2026-01-29 |
| AU2021325372A1 (en) | 2023-03-30 |
| EP3954364A1 (en) | 2022-02-16 |
| US12409142B2 (en) | 2025-09-09 |
| CL2023000450A1 (es) | 2023-10-20 |
| WO2022034209A1 (en) | 2022-02-17 |
| ECSP23016038A (es) | 2023-04-28 |
| EP4196098A1 (en) | 2023-06-21 |
| JP2023538030A (ja) | 2023-09-06 |
| US20240041775A1 (en) | 2024-02-08 |
| BR112023002654A2 (pt) | 2023-04-04 |
| ZA202303273B (en) | 2026-02-25 |
| PY2168235A (es) | 2022-04-25 |
| US20240350415A1 (en) | 2024-10-24 |
| CA3191326A1 (en) | 2022-02-17 |
| KR20230067614A (ko) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550161A1 (en) | Pharmaceutical composition and use thereof | |
| CY1110019T1 (el) | Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| MX2010002498A (es) | Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol. | |
| DE602006004451D1 (de) | Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen | |
| SI2148670T1 (sl) | Titracija tapentadola | |
| TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| MY204380A (en) | Nonracemic mixtures and uses thereof | |
| NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| MX2025006782A (es) | Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos | |
| BR112022007501A2 (pt) | Dispositivo ortodôntico de origem biológica e processo para termoformação do mesmo | |
| ATE526967T1 (de) | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum | |
| DOP2023000029A (es) | Nueva composición de anticonceptivo oral de liberación modificada | |
| BR112019021324A2 (pt) | Composições baseadas em xanthohumol | |
| BR112022019826A2 (pt) | Formulações de dapsona e métodos para o uso das mesmas | |
| PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
| BRPI0516545A (pt) | uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse | |
| PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
| MX2022001001A (es) | Composiciones farmaceuticas de liberacion modificada de acido tranexamico. | |
| CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
| ZA202404343B (en) | A non-swallowed, antacid chewing gum product, a process for its preparation and uses thereof | |
| WO2022235234A3 (en) | Preparation of new formulations usable in covid-19 treatment and determination of clinical effects thereof | |
| CL2025003743A1 (es) | Composición farmacéutica que comprende maribavir. |